Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Director | February 16, 2021 | February 18, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date February 16, 2021 · Filed February 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 211,800 |
Ending reported balance
After 2021-02-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-16 · Grant · Acquired 6,318 · Balance 206,318 F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. F2: The RSUs vest in full on April 1, 2022. Row 2 · 2021-02-16 · Grant · Acquired 5,482 · Balance 211,800 F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. F3: The RSUs vest in full on February 16, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.
F2: The RSUs vest in full on April 1, 2022.
F3: The RSUs vest in full on February 16, 2022.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXA CORP
Report date November 17, 2017 · Filed November 17, 2017
Section 16 reporting ended · disclosed 2017-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-11-17 transaction · row 1
1 source rowRow 1 · 2017-11-17 · Disposition to issuer · Disposed 86,124 · Balance 0 F1: Disposed of upon the effectiveness of the merger of 3DS Acquisition 3 Corp., Inc. ("3DS"), a wholly owned subsidiary of Dassault Systemes Simulia Corp. ("Dassault"), with and into the Issuer on November 17, 2017 pursuant to a merger agreement dated September 27, 2017 among Dassault, 3DS and the Issuer (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-17 · Disposition to issuer · Disposed 5,353 · Balance 0 F2: Each restricted stock unit represented a contingent right to receive one share of the Issuer's common stock. F3: Upon the effectiveness of the Merger, the restricted stock units became fully vested and were canceled in exchange for a cash payment of $129,810.25 (representing a price of $24.25 per restricted stock unit). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.32 | Direct | 0 |
Reported balance
After 2017-11-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-17 · Disposition to issuer · Disposed 2,582 · Balance 0 F4: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $23,057.26 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.50 | Direct | 0 |
Reported balance
After 2017-11-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-11-17 · Disposition to issuer · Disposed 15,384 · Balance 0 F5: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $273,066.00 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.38 | Direct | 0 |
Reported balance
After 2017-11-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-11-17 · Disposition to issuer · Disposed 38,461 · Balance 0 F6: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $494,993.07 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of upon the effectiveness of the merger of 3DS Acquisition 3 Corp., Inc. ("3DS"), a wholly owned subsidiary of Dassault Systemes Simulia Corp. ("Dassault"), with and into the Issuer on November 17, 2017 pursuant to a merger agreement dated September 27, 2017 among Dassault, 3DS and the Issuer (the "Merger").
F2: Each restricted stock unit represented a contingent right to receive one share of the Issuer's common stock.
F3: Upon the effectiveness of the Merger, the restricted stock units became fully vested and were canceled in exchange for a cash payment of $129,810.25 (representing a price of $24.25 per restricted stock unit).
F4: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $23,057.26 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option).
F5: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $273,066.00 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option).
F6: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $494,993.07 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2021 Filed Feb 18, 2021 20:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 5,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-21-000023 · edgar.xml · nonDerivative · entry 2 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,800 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. F3 · kind: The RSUs vest in full on February 16, 2022. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:28 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 6,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-21-000023 · edgar.xml · nonDerivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,318 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. F2 · kind: The RSUs vest in full on April 1, 2022. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 20:10 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 38,710 | $5.26 | $203,614.60 |
DisclosureSEC source: 0001661181-20-000045 · edgar.xml · nonDerivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.27, inclusive. The reporting person undertakes to provide to Organogenesis Holdings Inc. ("ORGO"), any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 17:10 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 42,726 | $3.25 | $138,859.50 |
DisclosureSEC source: 0001661181-20-000041 · edgar.xml · nonDerivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,290 Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:26 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 18,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-20-000019 · edgar.xml · nonDerivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,564 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on April 1, 2021. Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 16:57 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 1,032 | $6.07 | $6,267.54 |
DisclosureSEC source: 0001661181-19-000020 · edgar.xml · nonDerivative · entry 2 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $6.05 to $6.08, inclusive. The reporting person undertakes to provide to Organogenesis Holdings Inc. ("ORGO"), any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 16:57 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 3,958 | $6.14 | $24,302.12 |
DisclosureSEC source: 0001661181-19-000020 · edgar.xml · nonDerivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,968 Read SEC document |
| September 11, 2019 Filed Sep 11, 2019 19:12 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 3,133 | $5.80 | $18,171.40 |
DisclosureSEC source: 0001661181-19-000019 · edgar.xml · nonDerivative · entry 3 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,010 Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 19:12 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 8,877 | $5.17 | $45,895.87 |
DisclosureSEC source: 0001661181-19-000019 · edgar.xml · nonDerivative · entry 2 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,877 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $5.14 to $5.23, inclusive. The reporting person undertakes to provide to Organogenesis Holdings Inc. ("ORGO"), any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 19:12 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 1,000 | $4.95 | $4,950.00 |
DisclosureSEC source: 0001661181-19-000019 · edgar.xml · nonDerivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 20:26 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 32,000 | $4.70 | $150,505.60 |
DisclosureSEC source: 0001661181-19-000010 · edgar.xml · nonDerivative · entry 2 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $4.31 to $4.85, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 20:26 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | PurchaseClass A Common Stock | 50,000 | $4.31 | $215,705.00 |
DisclosureSEC source: 0001661181-19-000010 · edgar.xml · nonDerivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.48, inclusive. The reporting person undertakes to provide to Organogenesis Holdings Inc. ("ORGO"), any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 21:32 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $7.04 | $0.00 |
DisclosureSEC source: 0001661181-18-000052 · edgar.xml · derivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-12-10 F1 · derivative.exercise_date: The option becomes exercisable in equal yearly installments over three years from the date of grant. Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 16:38 UTC | EXA CORP EXA · Entity 169415 | Disposition to issuerStock Option (Right to Buy) · Derivative | 38,461 | $12.87 Strike: $11.38 | $494,993.07 |
DisclosureSEC source: 0001209191-17-061511 · doc4.xml · derivative · entry 5 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,461 shares Expires not disclosed F6 · price: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $494,993.07 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). F6 · derivative.exercise_date: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $494,993.07 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). F6 · derivative.expiration_date: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $494,993.07 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 16:38 UTC | EXA CORP EXA · Entity 169415 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,384 | $17.75 Strike: $6.50 | $273,066.00 |
DisclosureSEC source: 0001209191-17-061511 · doc4.xml · derivative · entry 4 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,384 shares Expires not disclosed F5 · price: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $273,066.00 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). F5 · derivative.exercise_date: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $273,066.00 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). F5 · derivative.expiration_date: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $273,066.00 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 16:38 UTC | EXA CORP EXA · Entity 169415 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,582 | $8.93 Strike: $15.32 | $23,057.26 |
DisclosureSEC source: 0001209191-17-061511 · doc4.xml · derivative · entry 3 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,582 shares Expires not disclosed F4 · price: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $23,057.26 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). F4 · derivative.exercise_date: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $23,057.26 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). F4 · derivative.expiration_date: Upon the effectiveness of the Merger, the option was canceled in exchange for a cash payment of $23,057.26 (representing the difference between the merger consideration of $24.25 per share and the per share exercise price of the option multiplied by the number of shares subject to the option). Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 16:38 UTC | EXA CORP EXA · Entity 169415 | Disposition to issuerRestricted Stock Units · Derivative | 5,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-061511 · doc4.xml · derivative · entry 2 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,353 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represented a contingent right to receive one share of the Issuer's common stock. F3 · price: Upon the effectiveness of the Merger, the restricted stock units became fully vested and were canceled in exchange for a cash payment of $129,810.25 (representing a price of $24.25 per restricted stock unit). F3 · derivative.exercise_date: Upon the effectiveness of the Merger, the restricted stock units became fully vested and were canceled in exchange for a cash payment of $129,810.25 (representing a price of $24.25 per restricted stock unit). F3 · derivative.expiration_date: Upon the effectiveness of the Merger, the restricted stock units became fully vested and were canceled in exchange for a cash payment of $129,810.25 (representing a price of $24.25 per restricted stock unit). Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 16:38 UTC | EXA CORP EXA · Entity 169415 | Disposition to issuerCommon Stock | 86,124 | $24.25 | $2,088,507.00 |
DisclosureSEC source: 0001209191-17-061511 · doc4.xml · nonDerivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of upon the effectiveness of the merger of 3DS Acquisition 3 Corp., Inc. ("3DS"), a wholly owned subsidiary of Dassault Systemes Simulia Corp. ("Dassault"), with and into the Issuer on November 17, 2017 pursuant to a merger agreement dated September 27, 2017 among Dassault, 3DS and the Issuer (the "Merger"). Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 16:32 UTC | EXA CORP EXA · Entity 169415 | GrantRestricted Stock Units · Derivative | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040834 · doc4.xml · derivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,353 Underlying: Common Stock · 5,353 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit converts into one share of Exa common stock. F2 · derivative.exercise_date: The restricted stock units shall become fully vested on June 15, 2018 or at the next annual meeting of the Exa stockholders, whichever is earlier. F2 · derivative.expiration_date: The restricted stock units shall become fully vested on June 15, 2018 or at the next annual meeting of the Exa stockholders, whichever is earlier. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 17:55 UTC | EXA CORP EXA · Entity 169415 | Exercise / conversionRestricted Stock Units · Derivative | 6,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040627 · doc4.xml · derivative · entry 2 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon vesting, each restricted stock unit converts into one share of Exa common stock. F2 · derivative.exercise_date: On June 14, 2016, the reporting person was granted 6,097 restricted stock units that vested in full on June 14, 2017. F2 · derivative.expiration_date: On June 14, 2016, the reporting person was granted 6,097 restricted stock units that vested in full on June 14, 2017. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 17:55 UTC | EXA CORP EXA · Entity 169415 | Exercise / conversionCommon Stock | 6,097 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-040627 · doc4.xml · nonDerivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon vesting, each restricted stock unit converts into one share of Exa common stock. Read SEC document |
| October 07, 2016 Filed Oct 7, 2016 16:52 UTC | EXA CORP EXA · Entity 169415 | PurchaseCommon Stock | 2,300 | $14.89 | $34,247.00 |
DisclosureSEC source: 0001209191-16-145415 · doc4.xml · nonDerivative · entry 7 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,027 Read SEC document |
| October 07, 2016 Filed Oct 7, 2016 16:52 UTC | EXA CORP EXA · Entity 169415 | PurchaseCommon Stock | 1,604 | $14.88 | $23,867.52 |
DisclosureSEC source: 0001209191-16-145415 · doc4.xml · nonDerivative · entry 6 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,727 Read SEC document |
| October 07, 2016 Filed Oct 7, 2016 16:52 UTC | EXA CORP EXA · Entity 169415 | PurchaseCommon Stock | 200 | $14.87 | $2,974.00 |
DisclosureSEC source: 0001209191-16-145415 · doc4.xml · nonDerivative · entry 5 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,123 Read SEC document |
| October 07, 2016 Filed Oct 7, 2016 16:52 UTC | EXA CORP EXA · Entity 169415 | PurchaseCommon Stock | 500 | $14.88 | $7,440.00 |
DisclosureSEC source: 0001209191-16-145415 · doc4.xml · nonDerivative · entry 4 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,923 Read SEC document |
| October 07, 2016 Filed Oct 7, 2016 16:52 UTC | EXA CORP EXA · Entity 169415 | PurchaseCommon Stock | 700 | $14.88 | $10,416.00 |
DisclosureSEC source: 0001209191-16-145415 · doc4.xml · nonDerivative · entry 3 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,423 Read SEC document |
| October 06, 2016 Filed Oct 7, 2016 16:52 UTC | EXA CORP EXA · Entity 169415 | PurchaseCommon Stock | 5,000 | $14.93 | $74,650.00 |
DisclosureSEC source: 0001209191-16-145415 · doc4.xml · nonDerivative · entry 2 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,723 Read SEC document |
| October 06, 2016 Filed Oct 7, 2016 16:52 UTC | EXA CORP EXA · Entity 169415 | PurchaseCommon Stock | 261 | $14.90 | $3,888.90 |
DisclosureSEC source: 0001209191-16-145415 · doc4.xml · nonDerivative · entry 1 MACKIE WAYNE D · CIK 0001240034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,723 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.